NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its proprietary Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial and viral infections. NovaBay company's lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also offers NVC-101, a proprietary solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions, as well as an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo, and other dermatological indications. NovaBay company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in August 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.

Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.

Scios Inc. company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Interleukin Genetics, Inc. was founded in 1986 and is headquartered in Waltham, Massachusetts. Interleukin Genetics, Inc., together with its subsidiaries, focuses on developing, acquiring, and commercializing personalized health products that help individuals improve and maintain their health through preventive measures in the United States and internationally. It conducts, researches, develops, markets, and sells genetic test panels primarily in inflammatory and metabolic areas to provide insight into health, wellness, and disease. The company markets and distributes genetic tests under the GENSONA brand, through a strategic partnership with Alticor; and PST tests through sales and marketing partners to dentists and periodontists. It offers genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. Tablets and capsules can be immediate or time-release; the company also makes liquid formulations and provides specialty packaging, including laminated foil, blister, and pouches. Its facilities have the capacity to produce everything from small pilot-scale batches all the way up to full-scale commercial production. Other services include drug development, feasibility studies, and product testing. Mikart will also walk customers through all the required regulatory processes.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

AlphaRx, Inc., a pharmaceutical company, engages in the research and development of therapeutic products in Canada. The company is developing novel formulations of existing drugs that are insoluble or poorly soluble in water, utilizing its proprietary Bioadhesive Colloidal Dispersion drug delivery systems. Its principal products include Indaflex, a topical cream for the treatment of osteoarthritis of the knee; and Zysolin, an inhaled Tobramycin nanoparticles intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients. Indaflex completed a Phase II Proof of Concept clinical trial and Zysolin is in pre clinical stage. The company was formerly known as Logic Tech International, Inc. and changed its name to AlphaRx, Inc. in January 2000. AlphaRx, Inc. was founded in 1997 and is based in Markham, Canada.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.